<DOC>
	<DOCNO>NCT02513940</DOCNO>
	<brief_summary>Torsades de pointes ( TdP ) potentially fatal ventricular arrhythmia associate correct QT ( QTc ) interval prolongation . More 50 commonly use drug available US market may cause QTc interval prolongation TdP . While TdP occur commonly woman , 33-45 % case TdP occur men . Older age risk factor drug-induced TdP men , possibly due decline serum testosterone concentration . Available evidence show inverse relationship QTc interval serum testosterone concentration . In addition , experimental data , include investigator ' laboratory , suggest exogenous testosterone progesterone administration may protective prolongation ventricular repolarization TdP . Specific Aim : Establish influence transdermal testosterone administration oral progesterone administration preventive method diminish degree drug-induced QT interval prolongation men 65 year age old . Hypothesis : Transdermal testosterone administration oral progesterone administration effectively attenuate drug-induced QT interval response old men . To test hypothesis , transdermal testosterone , oral progesterone placebo administer 3-way crossover study men 65 year age old . QTc interval response low-dose ibutilide assess . The primary endpoint individually-corrected QT interval ( QTcI ) response ibutilide , presence absence testosterone , presence absence progesterone : 1 ) Effect pre-ibutilide QTcI , 2 ) Effect maximum post-ibutilide QTcI , 3 ) Effect % change post-ibutilide QTcI , 2 ) Area QTcI interval-time curve .</brief_summary>
	<brief_title>Influence Testosterone Administration Drug-Induced QT Interval Prolongation Torsades de Pointes</brief_title>
	<detailed_description />
	<mesh_term>Death , Sudden</mesh_term>
	<mesh_term>Torsades de Pointes</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Jervell-Lange Nielsen Syndrome</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Ibutilide</mesh_term>
	<criteria>Men â‰¥ 65 year age Prostate cancer ; history prostate cancer ; History breast cancer ; benign prostatic hypertrophy ; Weight &lt; 60 kg Weight &gt; 135 kg Serum k+ &lt; 3.6 mEq/L ; Serum mg2+ &lt; 1.8 mg/dL ; Hemoglobin &lt; 9.0 mg/dL ; Hematocrit &lt; 26 % ; Hepatic transaminases &gt; 3x upper limit normal ; Baseline Bazett'scorrected QT interval &gt; 450 ms Heart failure due reduce ejection fraction ( left ventricular ejection fraction &lt; 40 % ) Family personal history longQT syndrome , arrhythmias sudden cardiac death ; Concomitant use QT intervalprolonging drug .</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Torsades de pointes</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Risk reduction</keyword>
	<keyword>Electrocardiography</keyword>
</DOC>